Vol. 3, No. 11-12
Nov.-Dec., 1999
| Number | Subject |
| 031101 | Ranbaxy Considering Option for Marketing Parvosin |
| 031102 | Pfizer Given Go-ahead by FIPB for Fully-owned Subsidiary |
| 031103 | Wockhardt Veterinary to Merge With Parent |
| 031104 | Piramal Group to Acquire Lupin's Property |
| 031105 | Novartis India to Spin Off Agri-business into New Entity |
| 031106 | Bayer Identifies India as Key Market |
| 031107 | Glenmark's Public Issue to Fund Research and Development |
| 031108 | Glaxo & Wellcome to Start Millennium with Restructuring |
| 031109 | Lupin Laboratories' Research and Development Plans |
| 031110 | Indian Pharma Companies Gear Up to Meet Challenges of Patent Act |
031101 Ranbaxy Considering Option for Marketing Parvosin
To market its new molecule RBX 2258, the company's first new chemical entity (NCE), Ranbaxy is considering the option of licensing it to a multinational company. The molecule has been named Parvosin after the company's former chairman and managing director, Parvinder Singh. The discussions would start in the early stages of the Phase-3 clinical trials scheduled in 2000.
031102 Pfizer Given Go-ahead by FIPB for Fully-owned Subsidiary
After a long review, the FIPB has approved the Pfizer proposal
for a fully-owned subsidiary in India. Minority shareholders and
chambers of commerce had raised the issue of the existing shareholders
of Pfizer Ltd (in which the multinational has a 40% stake) being
adversely affected if the fully-owned subsidiary was given the
go ahead. The proposal was referred to the board again for reconsideration.
Pfizer maintained that the operations of the two entities would
be different and would not compete with each other. Also Pfizer
Ltd was not a collaboration in that it didn't have a significant
Indian shareholder. The majority shareholder was Pfizer with the
rest comprising financial institutions, banks and retail investors.
Only in case there is a major Indian shareholder who is also the
collaborator, permission has to be obtained from the collaborator
to set up a fully-owned subsidiary.
031103 Wockhardt Veterinary to Merge With Parent
Wockhardt Veterinary (WVL), the closely held Wockhardt subsidiary
is being merged with the parent company. Shareholders of WVL will
be offered one share of Wockhardt in exchange for four of their
shares. WVL has sales of Rs 25 crore. The merger was approved
in an extraordinary general meting. The shareholders also approved
the merger of Wockhardt Healthcare with Wockhardt Life Science.
Along with the share of Merind, another Wockhardt subsidiary,
Wockhardt now has an 8.5 per cent share in the veterinary market
with sales of Rs 50 crore. Wockhardt has announed an interim dividend
of Rs 6.5 per share for the 18-month period ending December 1999.
031104 Piramal Group to Acquire Lupin's Property
The Piramal group is in talks to acquire a 50,000 square foot
property belonging to the Lupin group for its retail activities.
The property belongs to Landmark Builders, fully owned by the
Lupin group.
031105 Novartis India to Spin Off Agri-business into New Entity
With the hiving off of the Novartis AG and AstraZeneca Plc agri-business activities into a news subsidiary, Novartis India is also in the process of spinning off its agri-business activities in India. Agro-chemicals accounts for 50 per cent of Novartis' sales in India. Novartis will then concentrate on healthcare.
The spin-off will not have any impact on AstraZeneca's Indian
collaboration, Astra-IDL, as it has decided to sell its holding
in the joint venture. The new agri-business entity, formed by
spinning off from its parents Novartis AG and AstraZeneca Plc
will be known as Syngenta AG.
031106 Bayer Identifies India as Key Market
Bayer AG, the German multination has identified India, China and
Thailand as three prime locations in the company's plastics production
market in Asia. The Indian joint venture Bayer Sanmar Ltd could
become a major exporter as the polyurethane market in Asia has
improved. The multinational also see good prospects for high performance
engineering plastics.
031107 Glenmark's Public Issue to Fund Research and Development
Glenmark is planning to tie up with US generic drug manufacturers
to tap the generic formulation market abroad. The company is gearing
up to meet the challenges posed by the Patent Act. Another thrust
area is new drug delivery systems (NDDS) for which the company
proposes to construct a research and development facility in Goa.
The target markets are Canada and Europe and the company proposes
to manufacture Soft Gel capsules (capacity: 3600 lakh capsules
per annum) in compliance with US FDA specifications. The company
is also constructing a new research and development centre at
Thane near Mumbai at a cost of Rs 11.30 crore. The company is
tapping the equity market to fund these projects.
031108 Glaxo & Wellcome to Start Millennium with Restructuring
Glaxo & Wellcome is starting the new millennium with a strategic
restructuring exercise in its pharmaceutical sales and marketing
structure. The company is veering away from a trading faces-centred
approach to a therapy area focused approach. Accordingly Glaxo
Pharmaceuticals, Glaxo Allenburys and Burroughs Wellcome will
restructure into seven business units called the "Magnificient
7" with each having its own sales and marketing team. The
company's 200-product portfolio will be trimmed and reallocated
for more synergy. This, it is hoped, will generate more innovation
in marketing and take the early-mover advantage while launching
new products.
031109 Lupin Laboratories' Research and Development Plans
Lupin Laboratories is increasing its research and development spending from two per cent currently. It has already spent nearly Rs 48.5 crore on research and plant modernisation in the last two years. Its two research divisions will come out with three or four new products every year and it is also aiming at the oral control release systems market.
The company has 25 products waiting to go off-patent and aims
at a global market in which their products will have a good demand,
though entry barriers will be high. The generic market in the
US has a growth rate of 10 per cent to 12 per cent and will reach
sales of $ 16 billion in the coming three years. The company has
targeted products going off-patent, abbreviated new drug applications
(ANDAs) and control release systems (CRS) for the foreign market.
It is also planning to launch a series of oral cephalosporins
in the US and Europe. The company is in the process of filing
six ANDAs, which will later by marketed in collaboration with
a multinational.
031110 Indian Pharma Companies Gear Up to Meet Challenges of Patent Act
With the government amending the Patent Act (1970) to comply with
the requirements of the Trade Related Intellectual Property Rights
(TRIPS) of the World Trade Organisations (WTO), Indian companies
are designing new strategies for survival. Product patents will
soon be introduced in India. Hitherto only process patents were
recognised because of which an identical product could be manufactured
by another process. But now all that will change with the coming
of products patents. A similar product can no longer be manufactured
using a different process. Companies are trying out new products
in the various segments of the pharmaceutical industry. They are
targeting niche markets and tailoring their products to meet the
requirements of this market.
| Comp. | Acc. Year | Latest Annual
Result | Quarter 1 | Quarter 2 | Half Year | Quarter 3 | Quarter 4 | |||||||
| Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | |||
| Lupin Labs. | Apr.99
Mar.00 | - | - | 190 | 12.86 | - | - | - | - | - | - | - | - | |
| % chng. | - | - | - | +2.3 | +30 | - | - | - | - | - | - | - | - | |
| Orchid
Chem. | Apr.99
Mar.00 | - | - | - | - | - | - | 175.3 | 19.21 | - | - | - | - | |
| % chng. | - | - | - | - | - | - | - | +33 | +9 | - | - | - | - | |
| Pfizer | Dec.99
Nov.99 | - | - | - | - | - | - | - | - | 76.97 | 9.87 | - | - | |
| % chng. | - | - | - | - | - | - | - | - | - | +26 | +8 | - | - | |
| Abbott Labs. | Apr.99
Mar.00 | - | - | - | - | 58.24 | 2.88 | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | +8 | +73 | - | - | - | - | - | - | |
| Pun. Chem. | Apr.99
Mar.00 | - | - | - | - | 19.18 | 0.09 | 37.67 | .19 | - | - | - | - | |
| % chng. | - | - | - | - | - | -13 | -91 | -5 | -90 | - | - | - | - | |
| Unichem Labs. | Apr.99
Mar.00 | - | - | - | - | 56.38 | 4.88 | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | +8 | +35 | - | - | - | - | - | - | |
| Ranbaxy Labs. | Apr.99
Mar.00 | - | - | - | - | 409.7 | 77.9 | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | -1.6 | +54 | - | - | - | - | - | - | |
| Glaxo | Jan.99
Dec.00 | - | - | - | - | - | - | - | - | 248 | 16 | - | - | |
| % chng. | - | - | - | - | - | - | - | - | - | +32 | -26 | - | - | |
| Shashun
Chem. | Apr.99
Mar.00 | 165.7 | 7.50 | - | - | 42.89 | 4.55 | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | -1 | +82 | - | - | - | - | - | - | |
| Suven Pharma. | Apr. 99
Mar.00 | 30.98 | 2.50 | - | - | 9.73 | 1.02 | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | +13 | +54 | - | - | - | - | - | - | |
| Neuland Labs. | Apr.99
Mar.00 | 65.97 | 2.1 | - | - | 18.51 | n.a. | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | +8 | n.a. | - | - | - | - | - | - | |
| Cipla | Apr.99
Mar.00 | 617.2 | 114.9 | - | - | 199.7 | 35.75 | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | +23 | +14 | - | - | - | - | - | - | |
| Panacea
Biotec | Apr.99
Mar.00 | - | - | - | - | - | 3.66 | 57.95 | 5.70 | - | - | - | - | |
| % chng. | - | - | - | - | - | - | +35 | +39 | +36 | - | - | - | - | |
| Torrent
Pharma. | Apr.99
Mar.00 | - | - | - | - | 101.1 | 18.80 | - | - | - | - | - | - | |
| % chng. | - | - | - | - | - | +13 | +75 | - | - | - | - | - | - | |
| Knoll
Pharma | Jan.99
Dec.99 | - | - | - | - | - | - | - | - | 77.5 | 40.6 | - | - | |
| % chng. | - | - | - | - | - | - | - | - | - | +9 | +286 | - | - | |
| Parke
Davis | Apr.99
Mar.00 | 179.3 | 6.93 | - | - | 52.93 | 4.31 | 101.0 | 8.14 | - | - | - | - | |
| % chng. | - | - | - | - | - | +6 | +85 | +0.2 | +42 | - | - | - | - | |
| Makers
Labs | Apr.99
Mar.00 | 23.95 | 0.80 | - | - | 8.93 | 0.3 | 17.05 | 0.64 | - | - | - | - | |
| % chng. | - | - | - | - | - | +20 | +11 | +17 | +42 | - | - | - | - | |
| Sun
Pharma | Apr.99
Mar.00 | 335.6 | 59.04 | - | - | 112.8 | 22.79 | 215.8 | 42.8 | - | - | - | - | |
| % chng. | - | - | - | - | - | +35 | +53 | +41 | +60 | - | - | - | - | |
| Bal
Pharma | Apr.99
Mar.00 | 24.89 | 0.62 | - | - | 8.26 | 0.44 | 14.44 | 0.57 | - | - | - | - | |
| % chng. | - | - | - | - | - | +22 | +158 | +17 | +72 | - | - | - | - | |
| Vorin
Labs | Apr.99
Mar.00 | 72.85 | 2.35 | - | - | 15.56 | 0.19 | 35.1 | 12.5 | - | - | - | - | |
| % chng. | - | - | - | - | - | -43 | -76 | -20 | -42 | - | - | - | - | |
| Ipca
Labs | Apr.99
Mar.00 | 335.4 | 21.4 | - | - | 95.22 | 8.09 | 171.8 | 15.9 | - | - | - | - | |
| % chng. | - | - | - | - | - | +1 | +105 | +0.5 | +48 | - | - | - | - | |
| Dr. Reddy's | Apr.99
Mar.00 | - | - | - | - | 113.5 | - | 239.9 | - | - | - | - | - | |
| % chng. | - | - | - | - | - | +4 | - | +7 | - | - | - | - | - | |
| Comp. | Acc. Year | Latest Annual
Result | Quarter 1 | Quarter 2 | Half Year | Quarter 3 | Quarter 4 | |||||||
| Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | Sales
(Cr.) | Net
(Cr.) | |||
| J B Chem. | Apr.'99
Mar.'00 | 152.8 | 14.53 | - | - | 40.65 | 4.65 | 82.78 | 10.15 | - | - | - | - | |
| % chng. | - | - | - | - | - | +3 | +75 | +5 | +30 | - | - | - | - | |
| Dabur
India | Apr.'99
Mar.'00 | 914.7 | 51.60 | - | - | 261.6 | 18.91 | 495.1 | 440.1 | - | - | - | - | |
| % chng. | - | - | - | - | - | +6 | -21 | +12 | +91 | - | - | - | - | |
| Morepen
Labs. | Apr.'99
Mar.'00 | 256.5 | 34.3 | - | - | 84.6 | 12.2 | 155.5 | 21.6 | - | - | - | - | |
| % chng. | - | - | - | - | - | +24 | +43 | +28 | +43 | - | - | - | - | |
| Nich.
Piramal | Apr.'99
Mar.'00 | - | - | - | - | 124.2 | 14.12 | 237.1 | 25.57 | - | - | - | - | |
| % chng. | - | - | - | - | - | +12 | +25 | +12 | +23 | - | - | - | - | |
| Wock-
hardt. | Jul.'98
Dec.'99 | - | - | 209.0 | 34.0 | - | - | - | - | - | - | - | - | |
| % chng. | - | - | - | +36 | +45 | - | - | - | - | - | - | - | - | |
| Ind-Swift
Labs | Apr.'99
Mar.'00 | 42.65 | 12.3 | - | 15.58 | .8 | 29.85 | 1.55 | - | - | - | - | ||
| % chng. | - | - | - | - | - | +54 | +220 | +58 | +288 | - | - | - | - | |
| Veronica
Labs. | Apr.'99
Mar.'00 | 7.19 | .25 | - | - | 5.81 | .41 | 11.08 | .92 | - | - | - | - | |
| % chng. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| Auro-
bindo | Apr.'99
Mar.'00 | 550.0 | 50.14 | - | - | 174.2 | 18.61 | 357.3 | 37.2 | - | - | - | - | |
| % chng. | - | - | - | - | - | +20 | +63 | +44 | +85 | - | - | - | - | |
| Novartis
India | Apr.'99
Mar.'00 | - | - | - | - | - | - | 424 | 49 | - | - | - | - | |
| % chng. | - | - | - | - | - | - | - | - | - | - | - | - | - | |